Iressa, Bexxar may go before advisory cmte.
FDA is understood to be considering AstraZeneca's tyrosine kinase inhibitor Iressa for non-small cell lung cancer and Corixa's non-Hodgkin's lymphoma agent Bexxar (tositumomab) as potential Oncologic Drugs Advisory Committee topics this fall. The committee is tentatively scheduled to meet Sept. 23-24...
You may also be interested in...
Ex-Novartis executive and co-founder of investment bank MM Dillon & Co shares insights around where healthcare unicorns can be found and some core criteria to build such firms.
In this week's podcast edition of Scrip's Five Must-Know Things, hear about Sanofi’s rebates, Moderna’s business prospects, US views on coronavirus vaccine comparisons, Piot talk about virus variants, and new results for Amgen's asthma drug.
Right now, it appears that COVID-19 diagnostics are holding up against new variants of the virus being detected, but that may not always be the case scientists said at a recent webinar organized by Agena Bioscience. See what Martin Stürmer, laboratory head of IMD Labor in Frankfurt Germany, said about it here.